Articles By Shervin Assassi, MD

ILD damage fibrosis path

Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?

By Shervin Assassi, MD

Rheumatologists typically manage systemic autoimmune rheumatic diseases and associated interstitial lung disease with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.

Read Article
ILD damage fibrosis path

Antifibrotics - A New Class of Therapies in Rheumatology?

By Shervin Assassi, MD

Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Shervin Assassi, MD
  • Shervin Assassi, MD

  • Dr. Assassi is Director of the Division of Rheumatology and Professor of Medicine at UTHealth Houston. He also co-directs the UTHealth Scleroderma Program, which houses one of the largest specialized systemic sclerosis clinics in the USA. His laboratory focuses on the molecular profiling of longitudinally collected biospecimens for the identification of novel therapeutic targets and biomarkers. He is also a Steering Committee Member of several multicenter, international clinical trials focusing on the treatment of systemic sclerosis or SARD-ILDs.

×